Last reviewed · How we verify

NCT04286035

Two Different Blocks for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Arthroplasty

Completed Phase 4 Last updated 13 March 2020
What this trial tests

Phase 4 trial testing Bupivacaine Injection in Knee Replacement, Total in 70 participants. Completed in 1 October 2019.

Timeline
2 April 2019
Primary endpoint
29 September 2019
1 October 2019

Quick facts

Lead sponsorSisli Hamidiye Etfal Training and Research Hospital
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment70
Start date2 April 2019
Primary completion29 September 2019
Estimated completion1 October 2019
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Who can join

55 and older, any sex, with Knee Replacement, Total or Pain, Postoperative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The frequency of femoral nerve block and adductor canal block for analgesia after TKA(total knee arthroplasty) increases with the use of ultrasonography in regional anesthesia. In this study, we aimed to compare the effects of femoral nerve block and adductor canal block on postoperative analgesia in patients undergoing unilateral knee arthroplasty.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bupivacaine Injection

Trials testing the same drug.

Other Sisli Hamidiye Etfal Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04286035.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing